Comparative Pharmacology
Head-to-head clinical analysis: NEUPRO versus PRAMIPEXOLE DIHYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEUPRO versus PRAMIPEXOLE DIHYDROCHLORIDE.
NEUPRO vs PRAMIPEXOLE DIHYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rotigotine is a non-ergoline dopamine agonist with high affinity for dopamine D1, D2, D3, D4, and D5 receptors; also binds to serotonin 5-HT1A and alpha2-adrenergic receptors.
Non-ergoline dopamine agonist that selectively binds to D2 and D3 dopamine receptors, particularly D3, in the striatum and substantia nigra, mimicking dopamine's effects to improve motor function in Parkinson's disease.
Apply transdermally once daily; initial dose 2 mg/24h, titrated weekly by 2 mg/24h up to 6 mg/24h, maximum 8 mg/24h.
0.125 mg orally three times daily, titrated as tolerated to maximum 4.5 mg/day
None Documented
None Documented
Single dose: 5-7 hours (transdermal); steady state: 7-10 hours; effective half-life for dosing is 8 hours due to reservoir in skin
Terminal half-life: 8–12 hours in young adults; up to 15–18 hours in elderly. Clinical context: Once-daily dosing; steady-state in 2–4 days.
Renal: 45% (metabolites), Fecal: 40% (metabolites), Biliary: 15%
Renal: ~90% unchanged in urine; biliary/fecal: ~2%.
Category C
Category A/B
Dopamine Agonist
Dopamine Agonist